Affiliations
- Shanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
- Clinical Center of Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, China.
PMID: 36761167 PMCID: PMC9907168 DOI: 10.3389/fimmu.2022.1099991
Abstract
Background: Rabies is a lethal zoonotic disease, and although inactivated vaccines are available, they require multiple doses. This limits cost- and time-effectiveness, especially in low- and middle-income countries.
Methods: We developed a nucleoside-modified Rabies mRNA-lipid nanoparticle vaccine (RABV-G mRNA-LNP) encoding codon-optimized viral glycoprotein and assessed its immunogenicity and efficacy in mice, comparing it with a commercially available inactivated vaccine.
Results: A single vaccination of RABV-G mRNA in mice induced potent immune responses, providing full protection against lethal rabies challenge. A two-dose strategy could extend the duration of protective response up to a year.
Conclusion: A single-dose nucleoside-modified Rabies mRNA-LNP vaccine could offer prolonged and effective protection, demonstrating its potential as a superior alternative to traditional inactivated vaccines.
Keywords
Challenge model; mRNA vaccine; rabies; rabies virus glycoprotein; virus-neutralizing antibodies.
